<p>Inhibition of cytokine release by 0 to 40 μg/ml of enoxaparin fractions 1 and 4. Cytokines [IL-4 <b>(A)</b>, IL-5 <b>(B)</b>, IL-13 <b>(C)</b> and TNF- α <b>(D)</b>] were released by PBMCs of allergic asthmatic subjects (n = 5) after <i>ex-vivo</i> stimulation with PHA. Data is presented as percentage of PHA-stimulated control. *<i>p</i><0.05, **<i>p</i><0.01 and ***<i>p</i><0.001 versus PHA-stimulated control.</p
<p>Inhibition of IL-6 and IL-8 release by fraction 1 of enoxaparin (0 to 25 μg/mL) after <i>in-vitro...
T-cell-mediated inflammatory cytokines, such as interleukin (IL)-4, IL-5, IL-13 and tumor necrosis f...
<p>(a) IL-4 mRNA levels. (b) IL-6 mRNA levels. (c) IL-12α mRNA levels. (d) IL-13 mRNA levels. Result...
<p>Effect of different concentrations of enoxaparin and dalteparin on cytokine levels [IL-4 <b>(A)</...
<p><b>(A)</b> PHA-induced release of cytokines (logarithmic scale) from PBMCs of healthy (n = 5) and...
<p>PHA-induced release of IL-4, IL-5, IL-13 and TNF-α in PBMC culture supernatants of healthy (n = 1...
<p>PBMCs from allergic asthmatic subjects (n = 2) were stimulated with various concentrations of PHA...
<p>Effect of different concentration of enoxaparin on the release of IL-6 <b>(A)</b> and IL-8 <b>(B)...
<p>Suppression of TNF-α release by eight HP-SEC derived saccharides (dp2 to dp16) of enoxaparin <b>(...
<div><p>Background</p><p>Enoxaparin, a low-molecular-weight heparin, is known to possess anti-inflam...
Enoxaparin, a low-molecular-weight heparin, is known to possess anti-inflammatory properties. Howeve...
<p>PBMCs from asthma patients tended to produce more IL-13 than cells from healthy controls (1632 pg...
<p>Suppression of TNF-α release by completely desulfated, <i>N</i>-desulfated or 2-<i>O</i>/3-<i>O</...
<p><b>(A)</b> LDH activity of PBMC supernatants from asthmatic subjects (n = 5) expressed as the per...
<p>Treatment with 400 mg/kg/day AO for 5 days suppressed the expression of <i>IL-1β</i> mRNA. AO als...
<p>Inhibition of IL-6 and IL-8 release by fraction 1 of enoxaparin (0 to 25 μg/mL) after <i>in-vitro...
T-cell-mediated inflammatory cytokines, such as interleukin (IL)-4, IL-5, IL-13 and tumor necrosis f...
<p>(a) IL-4 mRNA levels. (b) IL-6 mRNA levels. (c) IL-12α mRNA levels. (d) IL-13 mRNA levels. Result...
<p>Effect of different concentrations of enoxaparin and dalteparin on cytokine levels [IL-4 <b>(A)</...
<p><b>(A)</b> PHA-induced release of cytokines (logarithmic scale) from PBMCs of healthy (n = 5) and...
<p>PHA-induced release of IL-4, IL-5, IL-13 and TNF-α in PBMC culture supernatants of healthy (n = 1...
<p>PBMCs from allergic asthmatic subjects (n = 2) were stimulated with various concentrations of PHA...
<p>Effect of different concentration of enoxaparin on the release of IL-6 <b>(A)</b> and IL-8 <b>(B)...
<p>Suppression of TNF-α release by eight HP-SEC derived saccharides (dp2 to dp16) of enoxaparin <b>(...
<div><p>Background</p><p>Enoxaparin, a low-molecular-weight heparin, is known to possess anti-inflam...
Enoxaparin, a low-molecular-weight heparin, is known to possess anti-inflammatory properties. Howeve...
<p>PBMCs from asthma patients tended to produce more IL-13 than cells from healthy controls (1632 pg...
<p>Suppression of TNF-α release by completely desulfated, <i>N</i>-desulfated or 2-<i>O</i>/3-<i>O</...
<p><b>(A)</b> LDH activity of PBMC supernatants from asthmatic subjects (n = 5) expressed as the per...
<p>Treatment with 400 mg/kg/day AO for 5 days suppressed the expression of <i>IL-1β</i> mRNA. AO als...
<p>Inhibition of IL-6 and IL-8 release by fraction 1 of enoxaparin (0 to 25 μg/mL) after <i>in-vitro...
T-cell-mediated inflammatory cytokines, such as interleukin (IL)-4, IL-5, IL-13 and tumor necrosis f...
<p>(a) IL-4 mRNA levels. (b) IL-6 mRNA levels. (c) IL-12α mRNA levels. (d) IL-13 mRNA levels. Result...